Drugs / CIP-200
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06942624 | May 2025 → Jun 2026 overdue | periprosthetic joint infection | Orthopaedic Innovation Centre | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIP-200 | “Our lytic phage preparation was provided by Cytophage Technologies (CIP-200).” NCT06942624 ↗ |
| Modality | Other / unclassified | “a bacteriophage therapy” NCT06942624 ↗ |
| Route | Intravenous | “via intravenous and intra-articular” NCT06942624 ↗ |